Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient
Romosozumab (RSB) is a monoclonal antibody to sclerostin that is approved for post-menopausal osteoporosis at high fracture risk. It is administered as a monthly 210 mg subcutaneous injection for 12 months. We report the response to half the standard dose of RSB in an underweight patient with severe...
Main Authors: | Bhanvi Ramchandani, Faryal Sardar Mirza |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-03-01
|
Series: | Bone Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352187224000032 |
Similar Items
-
Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives
by: Lim SY, et al.
Published: (2022-12-01) -
Profile of romosozumab and its potential in the management of osteoporosis
by: Lim SY, et al.
Published: (2017-04-01) -
Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
by: Annika Vestergaard Kvist, et al.
Published: (2021-04-01) -
Romosozumab in osteoporosis: yesterday, today and tomorrow
by: Dong Wu, et al.
Published: (2023-09-01) -
Papel del Romosozumab en la práctica clínica a la luz de la evidencia
by: Alejandro Román-González, et al.
Published: (2022-01-01)